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The role of protein kinase C (PKC) in interleukin-l/I- (11-l& tumor necrosis factor-a- (TNF-a)-, and lipopolysaccharide- (LPS)-induced vascular 
cell adhesion molecule-l (VCAM-1) expression on human umbilical vein endothelial cells (HUVEC) was studied. PKC inhibition or downregulation 
diminished VCAM-1 mRNA accumulation and protein expression. Interleukin-l/I, TNF-a, and LPS induce nuclear factor (NF)-rcB-like binding 
activity, which precedes VCAM-1 transcription. PKC inhibition did not prevent NF-rcB-like binding activity, indicating that this is PKC- 
independent, and NF-lcB-like binding activity is insufficient for transcription of VCAM-1. 
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1. INTRODUCTION 
Stimulation of human umbilical vein endothelial cells 
(HUVEC) by interleukin-lp (Il-1B) and tumor necrosis 
factor-a (TNF-a) induces a prothrombotic and proin- 
flammatory phenotype. The proteins expressed by 
HUVEC following stimulation with these cytokines in- 
clude tissue factor, plasminogen activator inhibitor-l, 
interleukin-8, interleukin-6, granulocyte-macrophage 
colony stimulating factor, and the adhesion molecules 
intercellular adhesion molecule-l (ICAM-l), endothe- 
lial leukocyte adhesion molecule- 1 (E-selectin), and vas- 
cular cell adhesion molecule-l (VCAM-1) [I]. Although 
the pattern of 11-l- and TNF-induced surface protein 
expression has been well characterized, the intracellular 
signal transduction pathways utilized by 11-l and TNF 
are unknown. 
A potential role for PKC in mediating activation of 
HUVEC by 11-1s and TNF-a is suggested by the fact 
that activators of PKC such as phorbol esters and mez- 
erein are also reported to induce expression of ICAM- 
and E-selectin in HUVEC [24. Additionally, inhibi- 
tion of PKC by the isoquinoline-sulfonamide derivative 
H7 reduces leukocyte adherence to LPS-, TNF-, or Il- 
l-stimulated HUVEC [5], and inhibition or downregu- 
lation of PKC inhibits TNF-cc-, II-l-, and LPS-induced 
endothelial cell expression of ICAM- [6]. We now re- 
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port that inhibition of PKC or downregulation of PKC 
by pretreatment with PMA significantly reduced the 
ability of TNF-a-, 11-l/?, or LPS to induce the surface 
expression of VCAM-I in HUVEC. Likewise, inhibi- 
tion of PKC or pretreatment with PMA reduced TNF- 
a-induced accumulation of VCAM-1 mRNA. In con- 
trast, induction of the surface expression of E-selectin 
by TNF-a, 11-l/3 and LPS was not diminished by inhib- 
itors of PKC. 
2. MATERIALS AND METHODS 
2.1. Culture of endothelial cells and ELISA 
Human umbilical vein endothelial cells were obtained and cultured 
as previously described [7]. Cytokines, LPS, or phorbol esters were 
added to confluent monolayers of HUVEC 30 min after the addition 
of staurosporine (Calbiochem Corp., San Diego, CA), calphostin C 
(Kamiya Biomedical Co., Thousands Oaks, CA), or Ro31-7549 
(Roche Products Ltd., Welwyn Garden City, UK) without washing. 
For downregulation studies, cytokines or LPS were added to the wells 
24 h after the addition of PMA (100 @ml) (Sigma Chemical Co., St. 
Louis, MO), without washing. Adhesion molecule expression was 
measured by ELISA using the anti-E-selectin monoclonal antibody 
(mAb) BBll [S] (a gift of R. Lobb and C. Benjamin, Biogen, Inc., 
Boston, MA) or the anti-VCAM-1 mAb 4B9 [7]. 
2.2. Total protein synthesis 
Total cellular protein synthesis was determined by precipitation of 
[‘5S]methionine-labeled proteins with trichloroacetic acid (10%). 
HUVEC were pre-incubated with lO,&iiml [“Slmethionine (DuPont 
Co., Wilmington, DE), for at least one hour prior to the addition of 
the protein kinase C inhibitors, and then TNF-a (10 &ml) was added 
for 4 h. The HUVEC were lysed and [r’S]methionine incorporation 
was determined by precipitation with trichloroacetic acid, followed by 
solubilization with 1 N NaOH and &scintillation counting. 
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Fig. 1. Phorbol ester-induced surface expression of VCAM-1. Human umbilical vein endothelial cells were treated with 10 ng/ml to lO@ml PMA 
or PDBU for up to 24 h. Surface expression of VCAM-1 was measured by ELISA using the anti-VCAM-1 MoAb 4B9. (A) Tie-course for induction 
of surface expression of VCAM-1 by PMA (circles) or PDBU (squares) (1 &ml) ( means + S.E.M. of 5 experiments). (B) Concentration-dependent 
induction of VCAM-1 after a 5.5 h incubation with PMA (circles) or PDBU (squares) at 37’C (mean of 2 experiments). 
2.3. Northern analysis 3. RESULTS 
For Northern analysis, HUVEC were plated on gelatin-coated 
dishes and incubated with B-l/?, TNF-a, LPS or PMA for 4 h. Total 
cellular RNA was isolated according to the method of Chomczynski 
and Sacchi [9]. RNA (10 pg/lane) was electrophoresed in a 1.0% or 
1.2% agarose-formaldehyde g l and transferred to nylon or nitrocellu- 
lose membranes by capillary blotting. cDNA fragments for E-selectin 
[lo], VCAM-1 [ll], or&actin were labeled with [“P]dCTP by random 
priming. E-selectin, VCAM-1 and /I-actin specific mRNA transcripts 
were detected by hybridization and autoradiography. 
3.1. Induction of VCAM-I surface protein expression by 
activators of PKC 
Similar to its ability to induce E-selectin and ICAM- 
expression on HUVEC [24], the phorbol ester PMA 
induced VCAM-1 surface protein expression in a time- 
and concentration-dependent manner. Induction was 
2.4. Nuclear protein extraction and gel mobility shift assay 
Nuclear protein extracts were prepared as previously described [12]. 
The nuclear protein extract (2Opg) was incubated in a binding reaction 
with the “P-end-labeled duplex oligonucleotide probe for the NF-KB 
consensus equence of the Ig promoter (5’-CAGAGGGGTCTTTC- 
CGAGAGGAAGCT-3’) provided by K. Bomsztyk (University of 
Washington, Seattle, WA), and then electrophoresed in a 4% poly- 
acrylamide gel as previously described, except hat the binding buffer 
contained 0.05% NP-40 [13]. The gels were dried and directly autora- 
diographed using Kodak X-AR film. 
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2.5. Cytosolic protein kinase C 
Protein kinase C activity was assayed in the cytosolic fraction after 
pretreatment with PMA. Subcellular extracts were prepared according 
to the methods of Ostrowski et al. [14]. Cytosolic PKC activity was 
assayed at 3O“C in a final volume of 50 ~1 containing 50 PM [y- 
32P]ATP, 10 mM MgCI,, 0.6 mM EDTA, 3.3 mM EGTA, 2 mM 
dithiothreitol, 20 mM HEPES, pH 7.5, and 0.7 mg/ml histone III-s or 
0.25 mg/ml histone III-s N-bromosuccinimide fragment. PKC activity 
was assayed in the presence or absence of 2 mM CaCl,, 100 PM 
phosphatidylserine, and 60 PM diolein. After a 5 min incubation, 40 
~1 of the reaction mixture was spotted onto phosphocellulose filter 
papers and immersed in a 75 mM phosphoric acid wash. The papers 
were washed five times, blotted dry, and counted in a liquid scintilla- 
tion counter. 
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2.6. Reagents 
Tumor necrosis factor-& was a gift of R. Lobb (Biogen Inc., Cam- 
bridge, MA), interleukin-lp was purchased from R&D Systems Inc. 
(Minneapolis, MN), lipopolysaccharide was purchased from List Biol- 
ogicals Inc. (Campbell, CA) and [35S]methionine was purchased from 
New England Nuclear (Wilmington, DE). All other reagents not pre- 
viously detailed were purchased from standard commercial sources. 
Fig. 2. Concentration-dependent inhibition of TNF-a-stimulated 
VCAM-1 surface expression by staurosporine and calphostin C. Cal- 
phostin C (0) or staurosporine (0) were added to HUVEC in increas- 
ing concentrations, in dim light, 30 min prior to the addition of TNF-a 
(10 ngfml). After an additional 5.5 h incubation at 37’C, surface 
protein expression of VCAM-1 was measured by ELISA. Data are 
expressed as the percent induction in the presence of calphostin C or 
staurosporine compared to the induction with TNF-a alone 
(mean + S.E.M., n = 3). The data are expressed as percent induction 
compared to TNF-a alone because the absolute OD, values are not 
directly comparable between assays. Induction of VCAM-I surface 
expression by TNF-a (10 rig/ml) in 16 separate experiments resulted 
in a mean OD,, value of 0.188 f 0.023. 
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Table I 
Inhibition of the surface expression of E-se&in and VCAM-1 on HUVEC by staurosporine, calphostin C and Ro31-7549 
TNF (10 ng/ml) II-l/I (10 @ml) LPS (100 @ml) TCA precipitable 
counts 
E-selectin VCAM-1 E-selectin VCAM- 1 E-selectin VCAM-1 (% of TNF control) 
Staurosporine (250 nM) 106 f 30% 51 + 14% 124 + 27% 22 f 16% 98 + 22% 23 zt 13% 117 + 38% 
(n = 3) (n = 3) (?I = 3) (n = 3) (n = 3) (?I = 3) (n = 3) 
Calphostin C (2 PM) 104 f 12% 36 f 15% 115% 56% 102% 25% 106% 
(n = 3) (n = 3) (n= 1) (n= 1) (n= 1) (n= 1) (n= 1) 
Ro31-7549 (10 PM) 94 k 12% 49?5% 103 f 20% 
(n = 2) (n = 2) (n = 3) 
Human umbilical vein endothelial cells were treated with staurosporine (10 nM to 1 PM), calphostin C (50 nM to 4 PM), or Ro3 l-7549 (1.25 PM 
to 25 PM) 30 min prior to the addition of TNF-a, 11-l/I, or LPS. After an additional 5.5 h incubation at 37’C, surface protein expression of E-selectin 
and VCAM-1 was measured by ELISA. Data are expressed as the percent induction in the presence of inhibitor compared to the induction with 
TNF-a, II-lb, or LPS alone. The concentrations of inhibitor listed were chosen because VCAM-1 surface expression was inhibited by approximately 
50% or greater for all 3 agonists tested. Alternatively, HUVEC were pre-incubated with 20 @i/ml [“Slmethionine for at least one hour before 
treatment of the plates. After a six hour incubation with TNF-a, 11-l/?, or LPS, total protein synthesis was measured after precipitation with 
trichloroacetic acid. At the concentrations tested, none of the inhibitors reduced protein synthesis compared to TNF-a alone. 
maximal after a 6 h incubation at 37’C, and declined 
to baseline levels by 18 h despite the continuous pres- 
ence of PMA (Fig. 1). Surface expression of VCAM-1 
was observed at 50 n&l, and was maximal with 1 
&ml PMA. Phorbol dibutyrate (PDBU) gave similar 
results to PMA, while phorbol itself was without effect. 
The non-phorbol PKC activator mezerein also induced 
VCAM-1 surface protein expression, with maximal ex- 
pression induced at 1 ,uM. The extent of total phorbol 
ester-induced VCAM-1 and E-selectin surface expres- 
sion is 2-6-fold less than the expression induced by 
optimal concentrations of TNF-a [15]. 
3.2. Effect of PKC inhibition or downregulation on sur- 
face expression of VCAM-I 
To investigate the role of PKC in the signal transduc- 
tion mechanisms by which Il-lp, TNF-cc, and LPS in- 
A. 
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1 
duce the surface expression of VCAM- 1 in HUVEC, we 
used staurosporine, calphostin C or Ro31-7549 to in- 
hibit PKC [l&18], or pretreatment with PMA to 
downregulate PKC. Fig. 2 illustrates the concentration- 
dependent inhibition of TNF-a-induced surface expres- 
sion of VCAM-1 by calphostin C or staurosporine. Sim- 
ilar results were obtained for inhibition of Il-lj?- and 
LPS-induced VCAM-1 surface expression (data not 
shown). In Table I, the concentrations of staurosporine, 
calphostin C and Ro31-7549 listed reduced TNF-a-, 
11-l/$, or LPS-induced surface expression of VCAM-1 
by 50% or greater, without significant effect on E-se- 
lectin surface protein expression, or on total TNF-a- 
induced protein synthesis. Expression of E-selectin sur- 
face protein was not affected until cytotoxic concentra- 
tions of the inhibitors were reached, indicating that the 
reduction in TNF-a-, 11-l/%, or LPS-induced VCAM-1 
6. 
02 
1 
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Fig. 3. Effect of pretreatment with PMA on induction of the surface expression of VCAM-1 and E-selectin by TNF-&. Human umbilical vein 
endothelial cells were treated for 24 h with PMA (100 &ml) and then TNF-a was added for an additional 5.5 h incubation at 37’C. Data are 
expressed as mean f S.E.M. (A) Induction of VCAM-1 by TNF-a in control (open circles) and PMA-pretreated (tilled circles) HUVEC 
(means + S.E.M. of 5 experiments). (B) Induction of E-selectin by TNF-a in control (open circles) and PMA-pretreated (filled circles) HUVEC 
(means f S.E.M. of 5 experiments). lP < 0.05 compared to controls. 
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Fig. 4. Effect of staurosporine on TNF-u-stimulated NF-KB-like binding activity. Human umbilical vein endothelial cells were stimulated with 
TNF-a (10 &ml) for 2 h, with or without pretreatment with staurosporine (250 nM to 750 nM) for 30 min. Nuclear proteins were extracted as 
described, incubated in a binding reaction with a radiolabeled NF-lcB oligonucleotide probe, and electrophoresed on a polyacrylamide gel. 
TNF-a-stimulated NF-KB-like binding activity in the nuclear protein extract which specifically competed with a nonlabeled NF-KB probe. 
Staurosporine did not prevent induction of this NF-KB-like binding activity. The table lists the band densities for this individual experiment, 
measured by phosphorimaging and normalized to the total probe loaded per lane. 
surface protein expression was not due to non-specific trating the selective ffect of a loss of PKC activity on 
toxicity of the inhibitors. VCAM- 1 expression. 
Pretreatment with PMA (100 @ml; 160 nM) for 24 
h was used to downregulate PKC [19]. Pretreatment of 
HUVEC with PMA (100 &ml) for 24 h resulted in an 
almost complete loss of cytosolic PKC activity using the 
N-bromosuccinimide fragment of histone III-s to meas- 
ure PKC activity. Phosphorylation of the N-bromosuc- 
cinimide fragment of histone III-s was only 5.6 f 3.3 
cprn/pg protein for HUVEC pretreated with PMA com- 
pared to 95.3 + 32.8 cpml,ug protein for control 
HUVEC (n = 4). 
3.3. Effect of downregulation or inhibition of PKC on 
induction of NF-rcB-like binding activity 
Pretreatment with PMA significantly reduced the 
ability of Il-ljI, TNF-a, and LPS to induce surface ex- 
pression of VCAM-1. After a pretreatment with PMA, 
induction of VCAM-1 by TNF-a was only 22 + 12%, 
by 11-1s 22 f 8%, and by LPS 33 + 5% compared to 
control cells (Fig. 3A). In contrast, pretreatment with 
PMA did not reduce TNF-a-induced E-selectin surface 
expression (Fig. 3B). Pretreatment of HUVEC for 24 h 
with the PKC agonists phorbol dibutyrate or mezerein 
also inhibited TNF-a-induced VCAM-1, but not E-se- 
lectin surface protein expression (data not shown), illus- 
Interleukin-I/?, TNF-ol, and LPS induced binding of 
nuclear protein extracts to a labeled NF-lcB oligonucle- 
otide consensus equence from the Ig promoter, which 
was specifically competed off by an unlabeled oligonu- 
cleotide containing the Ig NF-XB binding sequence 
(data not shown). A prominent constitutive band was 
also present that did not compete for the unlabeled 
NF-XB oligonucleotide probe, and was therefore desig- 
nated nonspecific. The PKC inhibitor staurosporine, at 
concentrations that almost completely blocked TNF-ol- 
induced VCAM-1 surface protein expression, did not 
reduce the ability of TNF-a to induce an NF-rcB-like 
binding activity, as depicted for one of four separate 
experiments in Fig. 4. By phosphorimager analysis 
(Molecular Dynamics, Sunnyvale, CA) and following 
normalization to levels of total probe loaded, TNF-a- 
induced NF-FcB-like binding activity was 122 f 38% in 
the presence of 250 nM staurosporine, 139 & 66% in the 
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presence of 500 nM staurosporine, and 143 f 54% 
(means f S.D.) in the presence of 750 nM staurosporine 
compared to 10 &ml TNF-cx alone. Staurosporine it- 
self induced a slight NF-FcB-like binding activity by a 
mechanism that is unclear at this time (Fig. 4, lanes 3, 
5 and 7). 
3.4. Effect of downregulation or inhibition of PKC on 
VCAM-1 mRNA accumulation 
Interleukin-lp, TNF-a, and LPS induced a signifi- 
cant increase in the accumulation of VCAM-1 mRNA 
within 4 h. No transcript was evident in HUVEC under 
normal, resting conditions (Fig. 5, lane 1). A 24 h pre- 
treatment with PMA completely abolished the ability of 
a subsequent 4 h incubation with PMA to induce accu- 
mulation of VCAM-1 mRNA (Fig. 5, lane 10). Pretreat- 
ment with PMA also greatly diminished the accumula- 
tion of VCAM-1 mRNA in response to 11-l/?, TNF-a, 
and LPS (Fig. 5, lanes 7, 8, 9). 
Similar to a pretreatment with PMA, the protein ki- 
nase C inhibitor staurosporine reduced the accumula- 
tion of VCAM-1 mRNA in response to TNF-a, at con- 
centrations that also inhibited the surface expression of 
VCAM-1. At 250 nM, staurosporine diminished TNF- 
cc-induced VCAM-1 mRNA accumulation by 
45 + 1.3%, and at 500 nM, by 81 + 12% (n = 3). At 750 
nM, VCAM-1 mRNA accumulation was diminished by 
88% (n = 1). In contrast to its effect on VCAM-1 
mRNA accumulation, staurosporine did not diminish 
E-selectin mRNA accumulation at 250 nM, and at 500 
nM E-selectin mRNA accumulation was not signifi- 
cantly reduced (81 ? 17% of TNF-a-induced mRNA 
accumulation, n = 3). Accumulation of E-selectin 
mRNA was not significantly reduced by staurosporine, 
consistent with its lack of inhibition of E-selectin sur- 
face protein expression. Regression analysis of the effect 
of staurosporine on VCAM-1 mRNA accumulation 
and surface protein expression revealed that inhibition 
of VCAM-1 mRNA accumulation and VCAM-1 sur- 
face protein expression were directly and linearly re- 
lated with a correlation coefficient (?) of 0.965. 
4. DISCUSSION 
Our results demonstrate a role for protein kinase C 
in 11-1/I-, TNF-cz-, and LPS-induced surface expression 
of VCAM- 1 on HUVEC. Inhibitors of PKC or pretreat- 
ment with PMA for 24 h, which downregulates PKC, 
greatly diminished the extent of 11-l/?-, TNF-a-, and 
LPS-induced mRNA accumulation and surface expres- 
sion of VCAM-1. An NF-K-B-like binding activity pre- 
cedes the accumulation of E-selectin mRNA induced in 
H WEC by Il- l/3, TNF-a, and LPS [ 131, and an NFxB- 
like factor has been shown to be essential, but not suffi- 
cient, for induction of E-selectin gene transcription [20]. 
The promoter region of the VCAM-1 gene also has 
consensus binding sequences for NF-JCB, and deletion 
or mutation of these NF-rcB binding sequences in the 
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Fig. 5. Effect of pretreatment with PMA on 11-l/?-, TNF-a- and LPS-induced accumulation of VCAM-1 mRNA. Human umbilical vein endothelial 
cells were stimulated with 11-l/3, TNF-a, or LPS for 4 h, with or without a prior pretreatment with PMA (100 @ml) for 24 h. Total cellular RNA 
was extracted as described, and probed with “P-labeled cDNA for human VCAM-1 and /3-actin. 
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VCAM-1 promoter prevents transcription [21,22]. 
However, neither staurosporine nor pretreatment with 
PMA prevented induction of this NF-FcB-like binding 
activity, indicating that induction of NF-FcB-like bind- 
ing activity is not dependent upon PKC activation, nor 
is induction of NF-FcB-like binding activity sufficient for 
transcription of the VCAM-1 gene. 
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